GlassScriptPhysician profile
Elliot Aleskow
NPI 1154334340
$2,587.12
in general payments reported to CMS, 2019-2025
31 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $298 · 2021: $265 · 2022: $327 · 2023: $587 · 2024: $615 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.08 | 2020-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $354.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $277.46 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $211.18 | 2020-2024 | |
| Gilead Sciences, INC. | $146.26 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $133.53 | 2023-2025 | Eliquis |
| Inspire Medical Systems, INC. | $107.18 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $100.41 | 2020-2025 | Shingrix |
| Esperion Therapeutics, INC. | $87.36 | 2020-2021 | |
| Abbott Laboratories | $73.79 | 2019-2024 | Freestyle Libre 3 |
| Axogen | $56.76 | 2022 | |
| Boston Scientific Corporation | $56.30 | 2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $48.20 | 2019-2020 | |
| Dermira, INC. | $45.11 | 2020 | |
| Hologic Sales and Service, LLC | $44.80 | 2020-2024 | Aptima |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $44.25 | 2022 | |
| Arbor Pharmaceuticals, INC. | $42.49 | 2020 | |
| Allergan, INC. | $36.76 | 2020 | |
| Viiv Healthcare Company | $34.68 | 2023 | Apretude |
| Dexcom, INC. | $29.06 | 2025 | Dexcom G6 Transmitter |
| Upsher-Smith Laboratories LLC | $27.12 | 2022 | |
| Astellas Pharma US INC | $26.80 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $22.69 | 2022 | |
| Vivus LLC | $21.76 | 2024 | Qsymia |
| Radius Health, INC. | $21.06 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.11 | 2022 | |
| Lilly USA, LLC | $17.98 | 2021 | |
| Philips North America LLC | $17.67 | 2023 | |
| Avion Pharmaceuticals | $16.46 | 2021 | |
| Lundbeck LLC | $16.26 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Aleskow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.